

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended): A method for the ~~treatment or~~ prevention of Alzheimer's disease, in a human, comprising administering to [[a]] the human in need thereof an effective amount of an agent which results in lowered serum insulin levels selected from at least one member of the group of troglitazone, ciglitazone, pioglitazone, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione, and englitazone.

2. (currently amended): ~~The method of claim 1, wherein said agent is~~ A method for the prevention of Alzheimer's disease, in a human, comprising administering to the human in need thereof an effective amount of chromium.

Claims 3-6 (cancelled)

7. (currently amended): The method of claim [6] 21, wherein said thiazolidinedione is troglitazone.

8. (currently amended): A method for the ~~treatment or~~ prevention of Alzheimer's disease, in a human, comprising restricting the metabolizable carbohydrates in the diet of the human to a level which results in lowered serum insulin levels.

9. (original): The method of claim 8, wherein the metabolizable carbohydrates in the diet are limited to no more than about 55 grams per day.

10. (original): The method of claim 8, wherein the metabolizable carbohydrates in the diet are limited to no more than about 30 grams per day.

11. (original): The method of claim 8, wherein the metabolizable carbohydrates in the diet are limited to no more than about 15 grams per day.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

12. (original): The method of claim 8, wherein the metabolizable carbohydrates in the diet are limited to no more than about 10 grams per day.

13. (currently amended): A method for the ~~treatment or~~ prevention of Alzheimer's disease, in a human, comprising administering to ~~[[a]]~~ the human in need thereof an effective amount of an agent which ~~results in lowered serum insulin levels~~ increases the insulin sensitivity of the human and restricting the metabolizable carbohydrates in the diet of the human.

14. (original): The method of claim 13, wherein said agent is selected from the group consisting of chromium, insulin-like growth factor, a dopamine agonist and a thiazolidinedione.

15. (original): The method of claim 13, wherein said agent is troglitazone.

16. (original): The method of claim 13, wherein the metabolizable carbohydrates in the diet are limited to no more than about 55 grams per day.

17. (original): The method of claim 13, wherein the metabolizable carbohydrates in the diet are limited to no more than about 30 grams per day.

18. (original): The method of claim 13, wherein the metabolizable carbohydrates in the diet are limited to no more than about 15 grams per day.

19. (original): The method of claim 13, wherein the metabolizable carbohydrates in the diet are limited to no more than about 10 grams per day.

Claim 20 (cancelled)

21. (new) A method for the prevention of Alzheimer's disease, in a human, comprising administering to the human in need thereof an effective amount of a thiazolidinedione selected from at least one member of the group of troglitazone, ciglitazone, pioglitazone, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione, englitazone, and the pharmaceutically acceptable salts thereof.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

22. (new): The method of claim 21, wherein said thiazolidinedione is pioglitazone.
23. (new): The method of claim 21, wherein said thiazolidinedione is pioglitazone hydrochloride.
24. (new): The method of claim 21, wherein said thiazolidinedione is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione.
25. (new): The method of claim 21, wherein said thiazolidinedione is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate.
26. (new): The method of claim 21, wherein said thiazolidinedione is pioglitazone or a pharmaceutically acceptable salt thereof.
27. (new): The method of claim 21, wherein said thiazolidinedione is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof.
28. (new): The method of claim 21, wherein said thiazolidinedione is troglitazone or a pharmaceutically acceptable salt thereof.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com